Clinical Trial Update: Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

This report covers the completion of a Phase 3 study evaluating the efficacy and safety of HLX03 in adults with moderate-to-severe plaque psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• HLX03 (adalimumab biosimilar)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED